Shete Ashwini, Ghate Manisha, Iwasaki-Hozumi Hiroko, Patil Sandip, Shidhaye Pallavi, Matsuba Takashi, Bai Gaowa, Pharande Pratiksha, Hattori Toshio
Indian Council of Medical Research-National Institute of Translational Virology and AIDS Research (ICMR-NITVAR, Formerly National AIDS Research Institute), Pune 411026, India.
Research Institute of Health and Welfare, Kibi International University, Takahashi 716-0018, Japan.
Reports (MDPI). 2024 Jul 29;7(3):61. doi: 10.3390/reports7030061.
We asked if SARS-CoV-2 seropositivity in HIV/TB co-infected patients plays a role in precipitating active tuberculosis in HIV-infected individuals and alters inflammatory status. A prospective study was conducted on HIV/TB co-infected patients presenting with pulmonary ( = 20) or extrapulmonary ( = 12) tuberculosis. Abbott SARS-CoV-2 IgG kits assessed the presence of anti-nucleoprotein antibodies. Inflammatory markers viz. osteopontin, total and full-length galectin-9, and C-reactive protein were tested at baseline and the end of antituberculosis treatment. The inflammatory score (INS) was assessed based on the percentage of reduction in the inflammatory markers' levels at the end of the treatment. Anti-SARS-CoV-2 antibodies were detected in five male patients diagnosed with pulmonary ( = 2) and extrapulmonary ( = 3) TB. None of them reported symptomatic COVID-19. Inflammatory marker levels did not differ significantly at baseline compared to those in seronegative patients. However, the INS correlated negatively with SARS-CoV-2 seropositivity ( = -0.386, = 0.039), indicating persistently raised inflammatory markers in these patients at the end of the treatment compared to seronegative individuals. Among the four markers studied, total galectin-9 levels failed to decrease significantly in these patients ( = 0.030). The majority of HIV/TB co-infected patients enrolled in our study (84.5%) were SARS-CoV-2-seronegative, indicating that SARS-CoV-2 infection might not have played a role in precipitating TB reactivation.
我们询问了HIV/TB合并感染患者中SARS-CoV-2血清阳性是否在促使HIV感染者发生活动性结核病方面起作用，并改变炎症状态。对出现肺结核（n = 20）或肺外结核（n = 12）的HIV/TB合并感染患者进行了一项前瞻性研究。使用雅培SARS-CoV-2 IgG检测试剂盒评估抗核蛋白抗体的存在情况。在基线和抗结核治疗结束时检测炎症标志物，即骨桥蛋白、总全长半乳糖凝集素-9和C反应蛋白。根据治疗结束时炎症标志物水平降低的百分比评估炎症评分（INS）。在5名诊断为肺结核（n = 2）和肺外结核（n = 3）的男性患者中检测到了抗SARS-CoV-2抗体。他们均未报告有症状的COVID-19。与血清阴性患者相比，基线时炎症标志物水平无显著差异。然而，INS与SARS-CoV-2血清阳性呈负相关（r = -0.386，p = 0.039），表明与血清阴性个体相比，这些患者在治疗结束时炎症标志物持续升高。在研究的四种标志物中，这些患者的总半乳糖凝集素-9水平未能显著降低（p = 0.030）。我们研究中纳入的大多数HIV/TB合并感染患者（84.5%）为SARS-CoV-2血清阴性，这表明SARS-CoV-2感染可能在促使结核复发方面未起作用。
